Search PubMedSearch

PubMed · 42684544

Psychological interventions for individuals affected by Huntington's disease: effects on depression, anxiety, and emotional well-being.

Abstract

INTRODUCTION: The literature provides limited evidence on the effectiveness of psychological interventions for individuals living with Huntington's Disease (HD). This study aims to examine the role of psychological support in improving the well-being of individuals and families affected by HD. METHODS: The study methodology builds on previous work conducted by the European Huntington Association (EHA). The study includes individuals across three categories: individuals at risk of HD, premanifest HD, or with an HD-negative genetic test. Eligible participants were offered eight online individual cognitive behavioural therapy (CBT) sessions followed by two group sessions. Assessments were performed at pre-intervention, after the individual sessions and after the group sessions. The primary outcomes were anxiety, depression, positive and negative affect, and quality of life. RESULTS: Twenty-one individuals participated in the study, of whom 33% (n = 7) had an HD-negative genetic test, 29% (n = 6) were at risk, and 38% (n = 8) had premanifest HD; the cohort was 57% women (n = 12). Analyses showed significant reductions in depression and anxiety, with medium to large effect sizes. Negative affect also decreased significantly with a large effect, while positive affect showed a non-significant trend toward improvement. Quality-of-life outcomes (physical and mental health components) did not change significantly. Overall, the strongest effects were observed for mood-related outcomes (depression, anxiety, and negative affect). CONCLUSION: Our data shows that a short-term CBT intervention led to improvements in anxiety, depression and negative affect. These findings enhance the evidence base available supporting the efficacy of psychological interventions that may be beneficial for individuals affected by HD. The article also outlines key lessons regarding intervention tailoring and study design to inform future research exploring the efficacy of psychological interventions for this population.

Explore related subjects

Keep this discovery

Explore connections, maps & timelines

BibTeXRIS

Andrada Ciucă, Ștefan Trif, Simona Samoilă, Mădălina Radu, Francisco Iruela, Mónica Rodríguez Lopera, César Aguilera Vega, Ruth Blanco, Filipa Júlio, Astri Arnesen, Ramona Moldovan. 2026-09-02. Psychological interventions for individuals affected by Huntington's disease: effects on depression, anxiety, and emotional well-being.. https://doi.org/10.1007/s12687-026-00923-6

Cite the original work for its findings. Save a collection to share your selection of sources.

KEEP EXPLORING

Related citations

Effectiveness of high-dose versus standard-dose influenza vaccines against hospitalisation according to frailty risk: a prespecified analysis of the randomised trial DANFLU-2.

BACKGROUND: Frailty is a major risk factor for influenza-related complications and can influence vaccine effectiveness. We aimed to assess the relative vaccine effectiveness (rVE) of high-dose (HD-IIV) versus standard-dose inactivated influenza vaccine (SD-IIV) in older adults aged 65 years or older according to frailty risk. METHODS: This study was a prespecified analysis of DANFLU-2, an open-label, individually randomised trial, conducted in Denmark during three consecutive influenza seasons (2022-23, 2023-24, and 2024-25). Adults aged 65 years or older were randomised (1:1) to the HD-IIV or SD-IIV group. The primary endpoint was hospitalisation for influenza or pneumonia. Frailty was defined according to the validated Hospital Frailty Risk Score (HFRS) based on ICD-10 codes within 10 years before randomisation. Participants were stratified into three HFRS categories, namely low (<5 points), intermediate (5-15 points), and high (>15 points) frailty risk. The rVE of HD-IIV versus SD-IIV against the primary endpoint was assessed across prespecified HFRS categories and treating HFRS as a continuous variable. Pearson's chi-square test was used to compare safety events across frailty risk groups and randomisation groups. FINDINGS: Among 332&#x2009;438 randomised participants (mean age 73&#xb7;7 years [SD 5&#xb7;8]; 161&#x2009;538 [48&#xb7;6%] were female), 276&#x2009;173 (83&#xb7;1%) had low frailty risk, 52&#x2009;395 (15&#xb7;8%) had intermediate frailty risk, and 3861 (1&#xb7;2%) had high frailty risk. The primary endpoint of hospitalisation for influenza or pneumonia occurred in 1424 (0&#xb7;5%) of 276&#x2009;173 participants with low frailty risk, 761 (1&#xb7;5%) of 52&#x2009;395 with intermediate frailty risk, and 163 (4&#xb7;2%) of 3861 with high frailty risk (relative risk [RR] for intermediate vs low frailty risk 2&#xb7;8 [95% CI 2&#xb7;6-3&#xb7;1]; RR for high vs low frailty risk 8&#xb7;2 [7&#xb7;0-9&#xb7;6]). HFRS as a continuous variable significantly modified the effect of HD-IIV versus SD-IIV against the primary endpoint with higher rVE estimates with increasing HFRS (pinteraction=0&#xb7;020). The rVE was 0&#xb7;2% (95% CI -10&#xb7;8 to 10&#xb7;2) among those with low frailty risk, 13&#xb7;1% (-0&#xb7;4 to 24&#xb7;8) among those with intermediate frailty risk, and 19&#xb7;9% (-10&#xb7;3 to 42&#xb7;1) among those with high frailty risk. No significant interaction was observed when HFRS was assessed according to the prespecified categorical frailty groups (pinteraction=0&#xb7;17). The proportion of participants with at least one serious adverse event increased across frailty risk groups (13&#x2009;366 [4&#xb7;8%] of 275&#x2009;795 for low frailty risk, 5475 [10&#xb7;5%] of 52&#x2009;315 for intermediate frailty risk, and 777 [20&#xb7;2%] of 3850 for high frailty risk; p<0&#xb7;0001), with similar proportions of serious adverse events in the HD-IIV and SD-IIV groups for each frailty risk group. INTERPRETATION: Among adults aged 65 years or older in Denmark, frailty risk might modify the effects of HD-IIV versus SD-IIV against hospitalisation for influenza or pneumonia, with higher rVE estimates with increasing frailty risk. These findings might support considering high-dose influenza vaccines for frail older adults. However, effect modification was not evident when frailty was assessed using prespecified categorical subgroups, and subgroup-specific estimates were imprecise, with 95% CIs crossing the null. These results should be considered exploratory, warranting further investigation. FUNDING: The DANFLU-2 trial was funded by Sanofi.

Journal Article